title: [Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin  in Patients with IIIa Lung Adenocarcinoma].
abstract: OBJECTIVE
  Bevacizumab has showed its efficacy in advanced non-squamous lung cancer. The aim of this study is to assess the safety of bevacizumab plus pemetrexed and carboplatin neoadjuvant chemotherapy in patients with lung adenocarcinoma.
  
  
  METHODS
  25 patients with IIIa lung adenocarcinoma undergoing lobectemy or pneumonectomy with mediastinal lymphadenectomy after induction bevacizumab (Bev) plus pemetrexed/carboplatin (PC) were selected. Toxicity of chemotherapy and postoperative complications were analyzed.
  
  
  RESULTS
  Grade 3 or 4 neoadjuvant-related adverse events included fatigue (3 patients), neutropenia (3 patients), hypertension (1 patient). The adverse events thought to be related to bevacizumab included epistaxis in 2 patients (grade 1: 1; grade 2: 1) and hypertension in 3 patients (grade 1: 2; grade 3: 1). Postoperative complications included pneumonia in 2 patients, bronchial stump insufficiency in 1 case, atelectasis in 2 cases, and arrhythmia in 1 case. Hemorrhage events, thromboembolic events and wound-healing problems were not observed in the perioperative period.
  
  
  CONCLUSIONS
  The treatment modality of neoadjuvant Bev-PC appears to be safe and tolerant in patients with stage IIIa lung adenocarcinoma.
authors.affiliation: Sun Yat-sen University Cancer Center, State Key laboratory of South China, Guangzhou 510060, China.
authors.forename: Songliang
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Sun Yat-sen University Cancer Center, State Key laboratory of South China, Guangzhou 510060, China.
authors.forename: Pengfei
authors.initials: P
authors.lastname: Xu
authors.affiliation: Sun Yat-sen University Cancer Center, State Key laboratory of South China, Guangzhou 510060, China.
authors.forename: Cheng
authors.initials: C
authors.lastname: Yuan
authors.affiliation: Sun Yat-sen University Cancer Center, State Key laboratory of South China, Guangzhou 510060, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Ou
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D000068437:Pemetrexed / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068437:Pemetrexed; D000068258:Bevacizumab; D016190:Carboplatin